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CRIOCONSERVATION OF SERRATULA DISSECTA SEEDS
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Endemic medical species Serratula dissecta seeds cryo-conservation problems are considered in this report. Optimal
conditions of freezing- defrosting for the best germination preservation of biological material were chosen. The biology of
freshly Serratula dissecta seeds germination after its deep freezing has been researched. Comparative analysis of original
seeds' germination dynamics and germination dynamics after cryo-conservation were carried out. On the basis of these
experiments long-term storage conditions of Serratula dissecta seeds were selected.
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Plants are the source of a broad spectrum of biologically active phytochemicals. For effective defense against
pathogens and abiotic stress, plants have developed complicated chemical strategies with different mechanisms of action. By
harnessing these phytochemicals, humans have used plants for medicinal purposes for over 30,000 years, and they remain a
valuable source for the development of modern therapeutics. Plant-derived materials are utilized as pharmaceuticals,
botanical drugs, dietary supplements (nutrac·euticals), functional food ingredients, and cosmeceuticals. The Global Institute
for Bioexploration (GIBEX), an international conglomerate of researchers, is involved in multiple botanical therapeutics
discovery and development programs.
Plants are the source of a broad spectrum of biologically active chemicals. Plants evolved as chemical factories
to harness energy from the sun for the production of a vast array of biological compounds (phytochemicals). Plants use
phytochemicals as molecular building blocks, protection against biotic and abiotic stress, maintenance of biological functions,
and evolutionary fitness necessary for growth and reproduction [1]. Chemical defense is an effective tool in the struggle of
plants against pathogens and herbivores, because plants are generally anchored to a specific location and cannot avoid or
escape their attackers [2]. Plants present an astonishing variety of secondary metabolites for defense purposes. For example,
more than 540 secondary metabolites have been identified just in Cannabis saliva L. alone [3]. Cannabinoid and terpene
content in C. saliva may vary depending on plant chemotype and growth stage [4]. Plants can also employ complex chemical
defense strategies involving multiple synergistic mechanisms of action. Scientists from Boston, MA (United States) have
shown that Berberis fremontii Torrey possesses at least two complementary mechanisms to defend itself from microorganism
attack [5]. The antibacterial activity of berberine alkaloids, which are membrane-acting hydrophobic cations and also DNA
intercalators, is synergized by 5'-methoxyhydnocarpin. a specific inhibitor of the bacterial efflux multidrug resistance pumps
responsible for the resistance to antibiotics. Plants harbor various multidrug resistance pump inhibitors [6], producing an
effective synergistic combination with antibiotic compounds. Owing to the complementary and synergistic biological effects
of plant defense phytochemicals, multicomponent plant extracts might be highly effective as therapeutic agents that can
maintain health and wellness or prevent and mitigate human diseases through more than one mechanism. Interactions of
chemical components in the extracts play an important role in the safety and efficacy of plant preparations. Triptolide, the
anti-rheumatoid arthritis alkaloid extracted from Tripterygium wi(fordii Hook F., is highly toxic to humans in purified form,
although the toxicity of nonpurified triptolide-containing extracts is significantly reduced. Because of its high toxicity,
purified triptolide has never been approved for therapeutic usage, whereas the multicomponent medicine based on T wilfordii
extracts has demonstrated therapeutic potential [7]. The effectiveness of multicomponent botanical preparations, as compared
to that of a single chemical entity, might be based on enhanced safety/tolerability, protection of active substances from
degradation by mammal enzymes, a faster transfer of the active substance across membranes, circumvention of host drug
resistance, and a variety of potentiating or synergizing interactions. Presently, there is a growing interest in mechanisms
underlying the potentiating effects of complex botanical extracts on gene expression involved in disease development or vital
organism functions [8, 9].
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Figure 1. Milestones in botanical therapeutics

Botanical therapeutics are increasingly relevant in modern times. The use of traditional medicine remains
widespread around the world. The World Health Organization estimates that up to 80% of the population in some regions of
the world depends upon traditional medicine for primary health care (10]. lfistorical experiences embedded in traditional
medicines may also help to shift the drug discovery paradigm from.
The single active pharmaceutical ingredient new-chemical-entity (NCE) to multicomponent drug design (11, 12].
With a long history of herbal usage for the management of a variety of diseases in indigenous cultures, the success rate of
developing new drugs from herbal medicinal preparations may, in theory, be higher than that from chemical synthesis [11,
12].
. The importance of applying the modem scientific method for developing therapeutics based on natural products was
emphasized by awarding The Nobel Prize in Physiology or Medicine 2015 to William C. Campbell and Satoshi Omura for
their discoveries concerning a novel therapy against infections caused by roundworm parasites, and to Y ouyou Tu for her
discoveries concerning a novel therapy against malaria [13]. Youyou Tu many times stressed the importance of applying
contemporary scientific methods in the study of natural products and traditional medicine. [14] She played an important role
in isolating artemisinin from sweet wormwood (Artemisia annua L.). The ever growing role of artemisinin in the struggle
against malaria [15, 16) is also an important example of the continuous need for botanical therapeutics.
Plant-derived products have dominated the pharmacopoeia for thousands of years [17]. For example, in a recent
study, compounds from two medicinal plants- yarrow (Achi//ea mi//efo/ium L.) and chamomile (Matricaria chamomi//a L.)were identified in a sample of Neanderthal dental calculus from the northern Spanish site of El Sidr'on [18, 19], thus
documenting the use of medicinal plants by Homo as early as 30,000 years ago. The major milestones in using plant producis
for human health are outlined in Figure 1. Even in the current era of combinatorial chemistry and computational (in silica)
drug design, more than 25% of new, small molecule-based medicines are directly or indirectly derived from substances of
plant origin [20], and natural products remain an important source of new pharmaceuticals [21]. Pharmaceuticals derived
from plants include alkaloids, phenolics, terpenes, steroids and a variety of phytochemical mixtures (Table 1). Rise of
biologics, drugs of mostly protein origin, stimulated development of plant-based production platforms as an alternative to
bacteria, yeasts, insects and mammalian cell cultures. Plants provide scalability, cost-effectiveness arid greater safety for
recombinant protein production.[22]
Today, thousands of plant extracts are used in therapeutic interventions all over the world [12]. Western medicine
demonstrates a growing trend for using polytherapy (combinations of drugs or drug cocktails) especially in managing
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chronic, non-communicable diseases and disorders including hypertension [23, 24], diabetes and cancer [25]. This trend,
along with the possibility of using synergistic combinations of plant extracts with synthetic drugs, provides new opportunities
for development and clinical use of botanicals [26].
Table I. Some of the most important biologically active compounds derived from plants ("Most often used as precursors in chemical
svnthesis of final products)
Chemical class

Bioactive comnound

Botanical soorce

Theraoeutic use
Anticholinergic

Alkaloids:

Atropine, hyoscyamine,
scopolamine

Tropane alkaloid

So1anaceac spp.

C!'lmntothecin•
Caosaicin

Indal alkaloid
Phenvlalkvl-amine alkaloid
Opium alkaloid
Cocaine alkaloid

CamDtotheca acuminata
Caosicum soo.
Paf)(lver somniferum
Erythroxylum coca
Colchicum autumnale
Cephaelis ioecacuanha

Codeine, morohine
Cocaine
Colchlcioe
Emetine

lsoauinoline alkaloid
Isoauinolinc alkaloid
Isoouinoline alkaloid

Galanthaminc

Quinine
.)Uinidine
Reserpine
Tubocurarine

~ hiinoline

alkaloid

Bisbenzyl isoquinolioe alkaloid

Bis-indole alkaloid
Indole alkaloid

Yohimbine

Local anaesthetic

Anti-2out
Anti-amoebic
Cholinesterase inhibitor

Smoking cessation therapy

Cholinergic

PhysostiJ(Tna venenosum
PUocarpus iaborandi
Cinchona son.
Cinchona spp.
Rauvo/fia serpentina
Chondodendron tomentosum, Strychnos
toxifera
Catharanthus roseus
Apocynaceae, Rubiaceae spp.

lndole alkaloid

Vinblastine, vincristine

Analg;esic, anti-tussive

Leucoium aestivum
Nicotiana sot>.

t'Vrrolidine alkaloid
Indole alkaloid
Imidazole alkaloid
Ouinoline alkaloid

Nicotine

Phvsosti=ine
Pilocarpine

Anti-neoolastic

Topical aoal~esic

Cholinenric

Anti-malarial
Cardiac depressant
Anti-bvnertensivc, osvchotrooic
Skeletal muscle relaxant
Anti-neoplastic

Aphrodisiac

Temenes and steroids:

Artemisinin
Diosgenin•, hecogenin•,
stil!tll.asterol'
Taxol and other taxoids•

I

Dilloxin, di2itoxin

I

I

Anti-malarial

Sesauitemene lactonc
Steroids

Artemisia annua
Dioscorea spp.

Oral contraceptives and hormonal

Diternenes

Taxus brevifolia

dru2s
Anti-neoplastic

Glvcosideo:
Steroidal 2lvcosides
DiJrita/is son.
Cassia anJ[UStifolia
Hvclroxv-anthracene 2lvcosides
Others and mixtures:

Sennosides A and B
lpecac

Mixture of ipecac alkaloids and other
components

Podonhvllotoxin'

Lirnao

I
I

Podoohv/lum oeltatum

Laxative
Emetic

Cephaelis ipecacuanha

I

Cardiotonic

I

Anti-neoolastic

In the United States, botanical therapeutic categories are mostly defined by the purpose of use and structural
complexity (Table 2). Botanical therapeutic products from the same source may have different regulatory status depending on
the intended use. For example garlic (Allium sativum L.) is well known for a variety of dietary and therapeutic properties [27,
28] and products from this plant are classified as food, dietary supplements, drugs, cosmeceuticals or food depending on
intended use.
Table 2. Categories of botanical therapeutics in the Uruted States
Cateeorv
Descrlotloo
Pharmaceuticals

....c:
<II

c:
0
a.

E

Single compounds intended to cure or prevent disease

E:iamole
Taxol, cocaine,
asoirin

Botanical drugs

Extracts intended to cure or prevent disease.

Polyphenone E

Dietary supplements
(nutraeeutlcalo)

Extracts intended to supplement diet. Possible health

Garlic extract

Functional food ingredients

Extracts which affect food characteristics. Possible health

claims.

use

0

claims.

Phytosterols,
marigold extracts

Extracts which supplement cosmetic products. No claims.

Aloe cream

uI

·.;::;

:;
'S

Ree:ulatfons

IND/NDA process
FDA approval
IND/NDA process
FDA approval
Pre-market FDA
notification or history of

CosmMeutlcals

Self-affumation by
expens

Pre-19S8 common use
Pre-market FDA aoproval
None; safety established
bv manufacturer

The Global Institute for Bioexploratlon (GIBEX) - a global network for plant-derived therapeutics discovery
and development
The Global Institute for Bioexploration (GIBEX) was established in 2004 by joint efforts of Rutgers, The State
University of New Jersey, and the University of Illinois at Urbana-Champaign. In addition to the founding institutions,
GIBEX includes North Carolina State University, the City University of New York, and 22 universities in 17 developing
countries across 4 continents. By pioneering the "Reverse the Flow" paradigm, GIBEX's core principles intend to bring
simple, reliable, predictive and field-deployable assays to different regions of the world using Screens-to-Nature (STN)
technology [29]. STN assays provide a broad functional characterization of field-generated plant extracts by detecting antimicrobial activities (inhibition of bacterial, fungal, and protozoa! growth), anti-nematodal activities, antioxidant/polyphenolic
compounds, total alkaloids, ultraviolet (UV) blockers, and various enzymatic activities related to targets associated with
chronic diseases (e.g., proteases and protease inhibitors, glucosidases and glucosidase inhibitors) [30, 31]. STN technology
relies on non-proprietary, innovative, and simple yet effective portable assays to detect pharmacologically active compounds
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from plant and other natural sources. Currently there are over 20 functional assays in the STN I GIBEX portfolio, and this
number continues to grow every year. Miniaturized and field deployable STN technology requires only 2 grams of plant
tissue to perform screening in the field. The STN technology can extract and test biological materials under conditions where
only battery-operated tools can be used.
The GIBEX mission is to foster research collaboration with scientists, students and traditional healers worldwide to
identify plants that hold promise for human health. GIBEX trains and equips scientists in participating countries with
innovative STN tools designed to work in forests , savannas, deserts, marshes and oceans. The goals of GIBEX include
encouragement of new initiatives in research and development of natural biologically active substances, maintenance of
biodiversity, and conservation of natural resources.
STN technology already has been successfully transferred to Bhutan, Botswana, Chile, Cuba, Ecuador, Kazakhstan,
Kenya, Kyrgyzstan, Namibia, South Africa, Tanzania, Uganda, and tribal nations of the United States. In Ecuador, the 20142015 GIB EX program built a network of a dozen research institutions, governmental organizations, and local communities to
detect the anti-nematodal, anti-microbial, and antioxidant activities of 48 edible and medicinal plants sold in local markets
using STN assays.(29] Transferring STN technologies to local communities was also instrumental in fostering a unique
collaboration with the Tsachilas of Santo Domingo, an indigenous group with vast traditional medicinal knowledge and
access to biodiversity.
Furthermore, a two-year STN program at the University of Botswana has shown the utility of the STN assays as
useful field screening tools that bring together multiple stakeholders from a wide array of disciplines (32]. The STN
technology helped to establish mutual trust and cooperation between Botswana scientists, traditional healers and other
indigenous knowledge holders . This was successfully accomplished in a setting where legislative regulations on indigenous
knowledge systems, bioexploration and access- and benefit-sharing mechanisms are largely absent.
Meanwhile, STN technologies have become the basis for organization of the Mediterranean BioXplore program,
headed by Hadassah College in Jerusalem, Israel (33], in collaboration with the Consortium of the Biodiversity and
Environmental Research Center, Palestinian Authority (34] , Leitat Technological Center, Spain , and the Hellenic Regional
Development Center, Greece. Using STN technologies, BioXplore researchers identified a number of endemic plants in the
Mediterranean region [31, 33, 34] with potentially novel pharmacological activities. The preliminary data obtained through
the STN-driven screening program has sparked in-depth study and validation of these plants for use in the pharmaceutical,
food and cosmetic sectors.
GIBEX is expanding its research activities to the Caribbean region by building a program in Cuba. where Cuban
healers and researchers at the Gallego Otero Medicinal Plant Farm have worked with United States scientists and
conservationists to validate the medicinal use of over 125 plants used traditionally for several generations by the local
community. GIBEX is continually open to establishing new programs in additional countries and seeks to sustain and expand
its success in the countries where it has already been implemented.
The educational component of GIBEX programs includes laboratory studies, hands-on field training, lectures,
seminars, scientific conferences, public relation activities, and communications with stakeholders, community leaders and
elected politicians.
The GIBEX strategy is to integrate the STN technology into regional university and technical school curricula in a
way that will stimulate student interest in biological sciences and provide a hands-on experience in scientific discoveries and
traditional knowledge validation. GIBEX programs center education about health and conservation in a local context and
effectively demonstrates the value of natural products for developing life-saving medicines for a variety of diseases and
conditions, including the neglected tropical diseases. The curriculum includes integrated learning and hands-on field training
in natural product bioexploration, human health and biodiversity inventory and conservation. Some elements of the STN
program that can be easily incorporated into the high school curriculum have also been used in Alaska (with Alaskan Native
tribal communities and schools) and North Dakota (in Lakota reservations and tribal community colleges) to stimulate
students' interest in science and experimental biology by using culturally-familiar and valued resources to build STEM
expertise [30, 35, 36].
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